Recommendations for research

The guideline committee has made the following recommendations for research.

Key recommendations for research

1 Clinical and cost effectiveness of inferior vena caval filters in people with venous thromboembolism

What is the short- and long-term clinical and cost effectiveness of inferior vena caval filters in people with venous thromboembolism (VTE)? [2020]

To find out why the committee made this research recommendation see rationale and impact.

Full details of the evidence and the committee's discussion are in evidence review H: inferior vena caval filters for people with VTE.

2 Clinical and cost effectiveness of direct-acting oral anticoagulants based on individual patient data

What is the clinical and cost effectiveness of direct-acting oral anticoagulants (DOACs) compared with each other, with low molecular weight heparin (LMWH) plus a vitamin K antagonist (VKA), with LMWH alone, with placebo and with aspirin for the initial and long‑term treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) based on individual patient data from existing trials? [2020]

To find out why the committee made this research recommendation see rationale and impact.

Full details of the evidence and the committee's discussion are in evidence review D: pharmacological treatment in people with suspected or confirmed DVT and/or PE.

3 Prediction tools compared with clinical judgement

What is the prognostic accuracy of a tool to predict both VTE recurrence and major bleeding compared with clinical judgement in people with unprovoked proximal DVT or PE? [2020]

To find out why the committee made this research recommendation see rationale and impact.

Full details of the committee's discussion are evidence review F: what factors determine the optimum duration of pharmacological treatment for DVT or PE in people with a VTE?

4 Lower-dose thrombolysis for people with acute PE and right ventricular dysfunction

Does lower-dose thrombolysis reduce the risk of major bleeding and improve outcomes for people with acute PE and right ventricular dysfunction? [2015]

5 Diagnosis of DVT

What is the clinical and cost effectiveness of a whole‑leg ultrasound scan compared with a proximal leg vein ultrasound scan in the diagnosis of acute DVT? [2012]

Other recommendations for research

Treatment strategy for people who use intravenous drugs

What is the optimal pharmacological treatment strategy for DVT or PE in people who use intravenous drugs? [2020]

To find out why the committee made this research recommendation see rationale and impact.

Full details of the committee's discussion are in evidence review D: pharmacological treatment in people with suspected or confirmed DVT and/or PE.

Predicting VTE recurrence and major bleeding

What is the prognostic accuracy of a tool to predict both VTE recurrence and major bleeding after 3 months of initial anticoagulation treatment and in the long term? [2020]

To find out why the committee made this research recommendation see rationale and impact.

Full details of the committee's discussion are in evidence review F: what factors determine the optimum duration of pharmacological treatment for DVT or PE in people with a VTE?

Thrombolytic therapy for DVT

What is the clinical and cost effectiveness of clot removal using catheter‑directed thrombolytic therapy or pharmacomechanical thrombolysis compared with standard anticoagulation therapy for the treatment of acute proximal DVT? [2012]

  • National Institute for Health and Care Excellence (NICE)